JP2002517245A - 治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法 - Google Patents
治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法Info
- Publication number
- JP2002517245A JP2002517245A JP2000553585A JP2000553585A JP2002517245A JP 2002517245 A JP2002517245 A JP 2002517245A JP 2000553585 A JP2000553585 A JP 2000553585A JP 2000553585 A JP2000553585 A JP 2000553585A JP 2002517245 A JP2002517245 A JP 2002517245A
- Authority
- JP
- Japan
- Prior art keywords
- gpi
- polypeptide
- domain
- antibody
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8865698P | 1998-06-09 | 1998-06-09 | |
| US60/088,656 | 1998-06-09 | ||
| US10308898P | 1998-10-05 | 1998-10-05 | |
| US60/103,088 | 1998-10-05 | ||
| US09/328,199 US6858210B1 (en) | 1998-06-09 | 1999-06-08 | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| US09/328,199 | 1999-06-08 | ||
| PCT/US1999/013194 WO1999064595A1 (en) | 1998-06-09 | 1999-06-09 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002517245A true JP2002517245A (ja) | 2002-06-18 |
| JP2002517245A5 JP2002517245A5 (cg-RX-API-DMAC7.html) | 2006-08-03 |
Family
ID=27376031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553585A Pending JP2002517245A (ja) | 1998-06-09 | 1999-06-09 | 治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6858210B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1092027B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002517245A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20010052713A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1310759A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE346922T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU772851B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2329942A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69934228T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2275348T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1092027E (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999064595A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006507232A (ja) * | 2002-07-19 | 2006-03-02 | ザ ジェネラル ホスピタル コーポレイション | オキシム結合体、およびそれらの形成および用途 |
| JP2007535468A (ja) * | 2003-03-07 | 2007-12-06 | カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング | タンパク質結合性のドキソルビシン−ペプチド−誘導体 |
| JP2025532422A (ja) * | 2022-10-10 | 2025-09-29 | 深▲せん▼市迪克曼生物科技有限公司 | 新規なセラミド、その調製方法及び使用 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5268454A (en) * | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
| KR100361933B1 (ko) * | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| CA2376057A1 (en) * | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
| EP1210124A2 (en) * | 1999-07-29 | 2002-06-05 | Epix Medical, Inc. | Targeting multimeric imaging agents through multilocus binding |
| CN1399562A (zh) | 1999-11-28 | 2003-02-26 | 拉卓拉药物公司 | 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物 |
| CA2414076A1 (en) * | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| AU2002229639A1 (en) * | 2000-12-13 | 2002-06-24 | De Haard, Johannes Joseph Wilhelmus | Camelidae antibody arrays |
| TWI221406B (en) | 2001-07-30 | 2004-10-01 | Epix Medical Inc | Systems and methods for targeted magnetic resonance imaging of the vascular system |
| US20030114405A1 (en) * | 2001-08-13 | 2003-06-19 | Linnik Matthew D. | Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function |
| AU2003303524A1 (en) * | 2002-12-27 | 2004-07-29 | La Jolla Pharmaceutical Company | Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
| WO2004089422A2 (en) * | 2003-03-30 | 2004-10-21 | La Jolla Pharmaceutical Co. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
| CA2591914C (en) * | 2005-01-24 | 2017-04-25 | Board Of Regents, The University Of Texas System | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use |
| JP4898785B2 (ja) * | 2005-04-18 | 2012-03-21 | バイオ−ラッド ラボラトリーズ,インコーポレイティド | リン脂質及び補因子タンパク質の共有結合による固相固定化 |
| WO2008036449A2 (en) * | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Chemical antibodies for immunotherapy and imaging |
| US20080015145A1 (en) * | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
| JP5461581B2 (ja) * | 2009-01-02 | 2014-04-02 | フライサン ディベロップメント カンパニー リミテッド | 自己免疫疾患を診断するための合成ペプチド、方法およびキット |
| WO2011163568A1 (en) * | 2010-06-24 | 2011-12-29 | University Of Kansas | Conjugates comprising an n-oxime bond and associated methods |
| CN105273080A (zh) * | 2014-07-14 | 2016-01-27 | 于珮 | 一种还原型β2-糖蛋白Ⅰ的制备方法 |
| US10098960B2 (en) | 2015-04-03 | 2018-10-16 | Ucl Business Plc | Polymer conjugate |
| TWI572617B (zh) * | 2016-01-20 | 2017-03-01 | 國立陽明大學 | 重組β-醣蛋白胜肽及其於抗腫瘤之應用 |
| CN105801694A (zh) * | 2016-05-03 | 2016-07-27 | 上海科新生物技术股份有限公司 | 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体 |
| WO2019028336A1 (en) * | 2017-08-03 | 2019-02-07 | The Cleveland Clinic Foundation | IMPROVED PEPTIDE EXPRESSION AND ANTIBODY DETECTION OF APO-H SPECIFIC SUBJECT |
| WO2022195051A1 (en) * | 2021-03-18 | 2022-09-22 | Université De Genève | Peptides and use thereof for diagnosing and treating antiphospholipid syndrome |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4191668A (en) | 1977-02-03 | 1980-03-04 | Scripps Clinic And Research Foundation | Induction of immunological tolerance |
| US5126131A (en) | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
| US5370871A (en) | 1983-01-24 | 1994-12-06 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
| US6022544A (en) | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
| US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
| US4751181A (en) | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
| EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| ATE134880T1 (de) | 1988-04-04 | 1996-03-15 | Lawrence A Potempa | Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen |
| CA2044142A1 (en) | 1989-10-19 | 1991-04-20 | Eiji Matsuura | Carrier for binding of anti-phospholipid antibodies, an immunoassay method using the same and a kit therefor |
| US5268454A (en) | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5162515A (en) | 1990-01-16 | 1992-11-10 | La Jolla Pharmaceutical Company | Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| CA2058769C (en) | 1990-04-06 | 1999-03-02 | Steven Anthony Krilis | Methods for determining phospholipids and antibodies thereof |
| CA2098281A1 (en) | 1990-12-17 | 1992-06-18 | Howard M. Dintzis | Suppression of immune responses of oligomeric forms of antigen of controlled chemistry |
| IE922292A1 (en) | 1991-07-15 | 1993-01-27 | Jolla Pharma | Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides |
| EP0600088B1 (en) | 1992-02-05 | 1998-12-30 | Yamasa Corporation | Solid-phase reagent and assay of antibody using the same |
| FR2701263B1 (fr) | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps. |
| EP1808183A3 (en) | 1993-09-08 | 2009-07-01 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| WO1995014231A1 (en) | 1993-11-16 | 1995-05-26 | Yamasa Corporation | Method of assaying antiphospholipid antibody and kit therefor |
| FR2722991B1 (fr) | 1994-08-01 | 1996-10-11 | Orstom | Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante |
| JPH08333390A (ja) | 1995-04-07 | 1996-12-17 | Hoechst Japan Ltd | ペプチド及びそれからなる自己免疫疾患治療剤 |
| US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| US5780319A (en) | 1996-04-19 | 1998-07-14 | Pasteur Sanofi Diagnostics | Immunoassays to detect antiphospholipid antibodies |
| EP0954531A1 (en) | 1996-06-06 | 1999-11-10 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
| DE19637770A1 (de) | 1996-09-16 | 1998-03-19 | Koenig & Bauer Albert Ag | Verfahren und Anlage zum automatischen Zu- und Abführen von Rollen |
| ATE262539T1 (de) | 1996-11-12 | 2004-04-15 | Hope City | Immunoreaktive peptid ctl epitope von menschlichem cytomegalovirus |
| GB9805477D0 (en) | 1998-03-13 | 1998-05-13 | Oxford Glycosciences Limited | Methods and compositions for diagnosis of rheumatoid arthritis |
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| IL125262A0 (en) | 1998-07-07 | 1999-03-12 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| IL126447A (en) | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
| US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| CA2373016A1 (en) | 1999-05-04 | 2000-11-09 | Genethor Gmbh | Method for diminishing specific immune reactions |
| CA2376057A1 (en) | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
| AUPQ272699A0 (en) | 1999-09-09 | 1999-09-30 | Unisearch Limited | Use of beta2GPI in diagnostic tests for autoimmune diseases |
| CN1399562A (zh) | 1999-11-28 | 2003-02-26 | 拉卓拉药物公司 | 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物 |
| US20010051351A1 (en) | 2000-03-27 | 2001-12-13 | Racis Stanley Paul | Antigen-specific immune complex-based enzyme-linked immunosorbent assay |
| US20020150898A1 (en) | 2000-04-18 | 2002-10-17 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| CA2414076A1 (en) | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| DE10048417A1 (de) | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Verbindungen mit verzweigtem Linker |
-
1999
- 1999-06-08 US US09/328,199 patent/US6858210B1/en not_active Expired - Lifetime
- 1999-06-09 EP EP99937843A patent/EP1092027B1/en not_active Expired - Lifetime
- 1999-06-09 AT AT99937843T patent/ATE346922T1/de active
- 1999-06-09 JP JP2000553585A patent/JP2002517245A/ja active Pending
- 1999-06-09 WO PCT/US1999/013194 patent/WO1999064595A1/en not_active Ceased
- 1999-06-09 KR KR1020007013980A patent/KR20010052713A/ko not_active Ceased
- 1999-06-09 CN CN99808415A patent/CN1310759A/zh active Pending
- 1999-06-09 DE DE69934228T patent/DE69934228T2/de not_active Expired - Lifetime
- 1999-06-09 CA CA002329942A patent/CA2329942A1/en not_active Abandoned
- 1999-06-09 ES ES99937843T patent/ES2275348T3/es not_active Expired - Lifetime
- 1999-06-09 AU AU43395/99A patent/AU772851B2/en not_active Ceased
- 1999-06-09 PT PT99937843T patent/PT1092027E/pt unknown
-
2004
- 2004-07-30 US US10/903,058 patent/US20050004351A1/en not_active Abandoned
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006507232A (ja) * | 2002-07-19 | 2006-03-02 | ザ ジェネラル ホスピタル コーポレイション | オキシム結合体、およびそれらの形成および用途 |
| JP2011105773A (ja) * | 2002-07-19 | 2011-06-02 | General Hospital Corp | オキシム結合体、およびそれらの形成および使用のための方法 |
| JP2007535468A (ja) * | 2003-03-07 | 2007-12-06 | カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング | タンパク質結合性のドキソルビシン−ペプチド−誘導体 |
| JP2025532422A (ja) * | 2022-10-10 | 2025-09-29 | 深▲せん▼市迪克曼生物科技有限公司 | 新規なセラミド、その調製方法及び使用 |
| JP7818877B2 (ja) | 2022-10-10 | 2026-02-24 | 深▲せん▼市迪克曼生物科技有限公司 | 新規なセラミド、その調製方法及び使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4339599A (en) | 1999-12-30 |
| WO1999064595A1 (en) | 1999-12-16 |
| AU772851B2 (en) | 2004-05-06 |
| DE69934228D1 (de) | 2007-01-11 |
| PT1092027E (pt) | 2007-02-28 |
| US20050004351A1 (en) | 2005-01-06 |
| US6858210B1 (en) | 2005-02-22 |
| DE69934228T2 (de) | 2007-10-04 |
| ATE346922T1 (de) | 2006-12-15 |
| EP1092027B1 (en) | 2006-11-29 |
| CA2329942A1 (en) | 1999-12-16 |
| WO1999064595A9 (en) | 2000-09-08 |
| KR20010052713A (ko) | 2001-06-25 |
| EP1092027A1 (en) | 2001-04-18 |
| CN1310759A (zh) | 2001-08-29 |
| ES2275348T3 (es) | 2007-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6858210B1 (en) | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same | |
| US6207160B1 (en) | aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | |
| KR20000016414A (ko) | Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법 | |
| WO1996040197A9 (en) | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | |
| WO1997046251A9 (en) | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | |
| US7517657B2 (en) | Peptides for detecting anti-double stranded DNA antibody and uses thereof | |
| US8828942B2 (en) | Means for treating synucleinopathies | |
| US6410775B1 (en) | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies | |
| US6455244B1 (en) | Methods for the detection of antibodies associated with autoimmune disorders and infectious agents employing immunoretroid peptides derived from antigens associated with said disorders and agents | |
| JPH02479A (ja) | snRNP−A抗原及びそのフラグメント | |
| US6825319B1 (en) | Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome | |
| JP2003503040A (ja) | 合成ペプチド免疫原およびそれに対する抗体 | |
| US5837686A (en) | Peptides and antibodies for treatment of rheumatoid arthritis | |
| AU2004201699A1 (en) | Therapeutic and diagnostic domain 1 Beta2GPI polypeptides and methods of using same | |
| JPH01199996A (ja) | ペプチドおよびその製法 | |
| MXPA00012040A (en) | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1&bgr;2 | |
| JPH08333393A (ja) | リポタンパク(a)の診断アッセイおよびそれに用いるペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060602 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060602 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090625 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091117 |